Results 201 to 210 of about 105,425 (257)

Histon-Deacetylase [PDF]

, 2018
openaire   +1 more source

immunoHuMiX: A personalizable gut‐on‐chip model for unraveling human microbiome–immune interactions

VIEW, EarlyView.
The study introduces a personalized gut model that brings together human immune cells and intestinal cells to better mimic how the body interacts with microbes. This system successfully maintained both human cells and a 17‐strain probiotic community, showing consistent immune responses across different donors.
Charlotte De Rudder, Kacy Greenhalgh, Joanna Baginska, Camille Martin‐Gallausiaux, Léa Grandmougin, Rémy Villette, Mara Lucchetti, Bérénice Hansen, Marek Ostaszewski, Viacheslav A. Petrov, Koji Atarashi, Lena Weidert, Audrey Frachet Bour, Dominik Ternes, Javier Ramiro‐Garcia, Antoine Malabirade, Takeshi Tanoue, Marc Mac Giolla Eain, Elisabeth Letellier, Matthew Barrett, Jérôme Lacombe, Frederic Zenhausern, Coralie Guérin, Markus Ollert, Carole Seguin‐Devaux, Kenya Honda, Paul Wilmes   +26 more
wiley   +1 more source

Role of Histone Deacetylase and Inhibitors in Cardiovascular Diseases. [PDF]

Cell Prolif
Zhang LY, Wang YY, Wen R, Zhang TN, Yang N.   +4 more
europepmc   +1 more source

Identification of Histone Deacetylase Inhibitor Targeting Type I Interferon and B Cell Abnormalities in Systemic Lupus Erythematosus. [PDF]

Arthritis Rheumatol
Hirayama T, Konaka H, Kato Y, Shibahara T, Nishizawa C, Tsujimoto K, Park J, Itotagawa E, Jo T, Nishide M, Nishida S, Shima Y, Narazaki M, Aoki W, Ishii KJ, Takamatsu H, Kumanogoh A.   +16 more
europepmc   +1 more source

Recent Insights into the Creation of Histone Deacetylase Inhibitors for the Treatment of Human Diseases. [PDF]

Int J Mol Sci
Yudaev P, Aleksandrova Y, Neganova M.
europepmc   +1 more source

Targeted Degradation of Histone Deacetylase 8 Using Proteolysis Targeting Chimeras Technology: A Promising Approach for Glioblastoma Treatment. [PDF]

Drug Des Devel Ther
Chotitumnavee J, Seemaung P, Settacomkul R, Sukprasert R, Itoh Y, Suzuki T, Srihirun S, Power C, Vivithanaporn P.   +8 more
europepmc   +1 more source

LDN-57444 sensitizes hepatocellular carcinoma cells to sorafenib by promoting ferroptosis through histone deacetylase 2 (HDAC2) inhibition. [PDF]

Biol Direct
Lin JC, Huang TS, Chen YB, Chen TY, Wu PS, Liu TP, Yang PM.   +6 more
europepmc   +1 more source

Histone deacetylase 4: A therapeutic target for cardiovascular diseases (Review). [PDF]

Int J Mol Med
Ma X, Wei R, Song A, Zhang X, Zou J, Hao S.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Histone deacetylase inhibitors

European Journal of Medicinal Chemistry, 2005
AbstractFor Abstract see ChemInform Abstract in Full Text.
BRESSI JEROME C, GANGLOFF ANTHONY R, KWOK LILY   +2 more
openaire   +6 more sources